Alan J Kivitz (Alan Kivitz)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 19

Top Topics

Rheumatoid Arthritis

Disease Activity

Top Venues

Rheumatology and therapy

The Journal of rheumatology

Therapeutic advances in musculoskeletal disease

Annals of internal medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Gerd-Rüdiger R Burmester, Filip E Van den Bosch, Diamant Thaҫi, Anna K Shmagel, Yanxi Liu, Nasser Khan, Heidi S Camp, Alan J Kivitz
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT). The Journal of rheumatology 51 (7) (2024)
Alan J Kivitz, Joel M Kremer, Clarence W Legerton, Luminita Pricop, Atul Singhal
Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies. Rheumatology and therapy 11 (3) (2024)
Alan J Kivitz, Joel M Kremer, Clarence W Legerton, Luminita Pricop, Atul Singhal
Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies. Rheumatology and therapy 11 (3) (2024)
Andrew J K Ostor, Filip Van den Bosch, Kim A Papp, Cecilia Asnal, Ricardo Blanco-Alonso, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan J Kivitz
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Alan J Kivitz, Joel M Kremer, Clarence W Legerton, Luminita Pricop, Atul Singhal
Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies. Rheumatology and therapy 11 (3) (2024)
Andrew J K Ostor, Filip Van den Bosch, Kim A Papp, Cecilia Asnal, Ricardo Blanco-Alonso, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan J Kivitz
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Andrew J K Ostor, Filip Van den Bosch, Kim A Papp, Cecilia Asnal, Ricardo Blanco-Alonso, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan J Kivitz
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and therapy (2024)
Alan J Kivitz, Joel M Kremer, Clarence W Legerton, Luminita Pricop, Atul Singhal
Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies. Rheumatology and therapy (2024)
Alan J Kivitz, Joel M Kremer, Clarence W Legerton, Luminita Pricop, Atul Singhal
Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies. Rheumatology and therapy 11 (3) (2024)
Gerd-Rüdiger R Burmester, Filip E Van den Bosch, Diamant Thaҫi, Anna K Shmagel, Yanxi Liu, Nasser Khan, Heidi S Camp, Alan J Kivitz
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT). The Journal of rheumatology 51 (7) (2024)
Andrew J K Ostor, Filip Van den Bosch, Kim A Papp, Cecilia Asnal, Ricardo Blanco-Alonso, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan J Kivitz
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Andrew J K Ostor, Filip Van den Bosch, Kim A Papp, Cecilia Asnal, Ricardo Blanco-Alonso, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan J Kivitz
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Alan J Kivitz, Jacques Eric Gottenberg, Martin Bergman, Chunfu Qiu, Hubert van Hoogstraten, Ron de Nijs, Louis Bessette
Real-world Effectiveness of Sarilumab in RA: Results from the Open-label, Prospective, Single-arm Observational PROFILE Study. Rheumatology and therapy (2024)
Gerd-Rüdiger R Burmester, Filip E Van den Bosch, Diamant Thaҫi, Anna K Shmagel, Yanxi Liu, Nasser Khan, Heidi S Camp, Alan J Kivitz
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT). The Journal of rheumatology (2024)
Alan J Kivitz, Alvin F Wells, Juan de J Vargas, Herbert S B Baraf, Maureen Rischmueller, Justin Klaff, Nasser Khan, Yihan Li, Kyle Carter, Alan Friedman, Patrick Durez
Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study. Rheumatology and therapy (2023)
Anisha B Dua, Kerri Ford, Stefano Fiore, Dimitrios A Pappas, Jud C Janak, Taylor Blachley, Carla Roberts-Toler, Kelechi Emeanuru, Joel M Kremer, Alan J Kivitz
Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study. Rheumatology and therapy (2023)
Alan J Kivitz, Alvin F Wells, Juan de J Vargas, Herbert S B Baraf, Maureen Rischmueller, Justin Klaff, Nasser Khan, Yihan Li, Kyle Carter, Alan Friedman, Patrick Durez
Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study. Rheumatology and therapy (2023)
Jeffrey R Curtis, Stacey S Cofield, S Louis Bridges, John R Bassler, Atul A Deodhar, Theresa L Ford, Joseph Huffstutter, Allen Jankeel, Alan J Kivitz, Shaila Kamal, Stephen Lindsey, Ilhem Messaoudi, Norma Mendoza, Kaleb D Michaud, Ted R Mikuls, David Ridley, William Shergy, Sarah A R Siegel, Kevin L Winthrop
The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy : A Randomized Controlled Trial. Annals of internal medicine 174 (11) (2021)
Alan J Kivitz, Louis Kwong, Tammi Shlotzhauer, Joelle Lufkin, Amy Cinar, Scott Kelley
A randomized, phase IIa study to assess the systemic exposure of triamcinolone acetonide following injection of extended-release triamcinolone acetonide or traditional triamcinolone acetonide into both knees of patients with bilateral knee osteoarthritis. Therapeutic advances in musculoskeletal disease 11 (2019)